化疗及放化疗联合治疗局部晚期非小细胞肺癌的临床研究

【目的】比较单纯化疗与放化疗联合治疗局部晚期非小细胞肺癌（NSCLC）的疗效及毒性反应。【方法]56例不能手术的局部晚期NSCLC患者按治疗方法不同分为单纯化疗组31例（A组），放化疗联合组25例（B组），对比两组疗效及安全性。【结果】治疗有效率、中位生存期及1、3年生存率A组分别为38．7％、8．8个月、29％和0，B组分别为68％、13．5个月、56％和8％，B组较A组明显提高，差异有显著性（P〈0．05）。白细胞减少、血小板减少及消化道反应A组发生率分别为48．4％、16．1％和71％，B组分别为72％、20％和80％，两组相比差异均无显著性（P〉0．05）。【结论】对不能手术的局部晚期NSCLC采用放化疗联合治疗优于单纯化疗，且毒副反应能耐受。

Clinical Study of Chemotherapy and Chemoradiotherapy for the Treatment of Local Advanced Non-small Cell Lung Cancer

Objective] To compare the efficacy and toxic reaction of single chemotherapy vs. chemoradio- therapy for the treatment of local advanced non small cell lung cancer（NSCLC）. Methods] Totally 56 patients with local advanced NSCLC who could not undergo the operation were divided into single chemotherapy group（group A, n =31） and chemoradiotherapy group（group B, n --25） according to different therapy meth ods. The efficacy and safety were compared between two groups. Results] The effective rate, median survival, 1-year survival rate and 3-year survival rate in the group A were 38.7%, 8.8 mouths, 29% and 0, respectively, which were higher than those in the group B（68%, 13. 5 months, 56% and 8%, respectively）, and there were significant differences （ P 〈0. 05）. The incidence of leucopenia, thrombocytopenia and digestive tract reaction in group A were 48.4%, 16. 1% and 71%, respectively, while those of group B were 72%, 20% and 80%, respectively, and there were no significant differences between two groups （P 〉 0. 05）. Conclusion] Chemoradiotherapy for the treatment of local advanced NSCI.C is more effective than simple chemotherapy, and its toxic reactions can be tolerated.